Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure.

Br J Clin Pharmacol · 2020 · PMC7318993 · PMID 32068914

Europe PMC DOI

hedged sentences

0.0640

closest p · 1.3× alpha

0.0640

boldest claim

The sentences

a nonsignificant trendP = .064so close (0.05 < p ≤ 0.1)

27 , 28 , 29 A significant effect was only observed with 10 mg licogliflozin, although a nonsignificant trend ( P = .064) was also seen with the 50 mg dose.

also in 5,406 other papers

failed to reach statistical significanceP = .064so close (0.05 < p ≤ 0.1)

An apparent reduction in NT‐proBNP from baseline was also seen in the 50 mg licogliflozin group compared to placebo at week 12, but this failed to reach statistical significance (geometric mean ratio 0.64 [95% confidence interval: 0.40, 1.03]; P = .064; Table S3 ).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.